Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries

Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Lars Christian Lund, Christian Holm Hansen, Mia Aakjær, Jesper Kjær, Catherine Cohet, Mathijs Goossens, Morten Andersen, Jesper Hallas, Hinta Meijerink, Rickard Ljung, Anders Hviid
doi: https://doi.org/10.1101/2022.11.24.22282651

Data Availability

No additional data available. Owing to data privacy regulations in each country, the raw data cannot be shared.

Back to top
Posted November 29, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Comparative effectiveness of heterologous booster schedules with AZD1222, BNT162b2, or mRNA-1273 vaccines against COVID-19 during omicron predominance in the Nordic countries
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Lars Christian Lund, Christian Holm Hansen, Mia Aakjær, Jesper Kjær, Catherine Cohet, Mathijs Goossens, Morten Andersen, Jesper Hallas, Hinta Meijerink, Rickard Ljung, Anders Hviid
medRxiv 2022.11.24.22282651; doi: https://doi.org/10.1101/2022.11.24.22282651
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area